View Item 

Show simple item record

Prevalence and clinical features of patients with concurrent HBsAg and anti‐HBs: Evaluation of the hepatitis B research network cohort
dc.contributor.authorLee, William M.
dc.contributor.authorKing, Wendy C.
dc.contributor.authorSchwarz, Kathleen B.
dc.contributor.authorRule, Jody
dc.contributor.authorLok, Anna S. F.
dc.date.accessioned2020-09-02T15:02:00Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-09-02T15:02:00Z
dc.date.issued2020-09
dc.identifier.citationLee, William M.; King, Wendy C.; Schwarz, Kathleen B.; Rule, Jody; Lok, Anna S. F. (2020). "Prevalence and clinical features of patients with concurrent HBsAg and anti‐HBs: Evaluation of the hepatitis B research network cohort." Journal of Viral Hepatitis 27(9): 922-931.
dc.identifier.issn1352-0504
dc.identifier.issn1365-2893
dc.identifier.urihttps://hdl.handle.net/2027.42/156489
dc.description.abstractThe prevalence of concurrent HBsAg and anti‐HBs in plasma of persons with chronic hepatitis B virus (HBV) infection is variable and its clinical significance enigmatic. We examined the prevalence and clinical and virological features of concurrent HBsAg and anti‐HBs in children and adults with chronic HBV infection living in North America. A total of 1462 HBsAg positive participants in the Hepatitis B Research Network paediatric and adult cohorts were included (median age 41 (range 4‐80) years, 48% female, 11% white, 13% black, 73% Asians). Only 18 (1.2%) were found to be anti‐HBs positive (≥10 mIU/mL) at initial study evaluation. Distributions of sex, race, HBV genotype and ALT were similar between participants with and without concurrent anti‐HBs. Those who were anti‐HBs positive appeared to be older (median age 50 vs 41 years, P = .06), have lower platelet counts (median 197 vs 222 × 103/mm3, P = .07) and have higher prevalence of HBeAg (44% vs 26%, P = .10). They also had lower HBsAg levels (median 2.0 vs 3.5 log10 IU/mL, P = .02). Testing of follow‐up samples after a median of 4 years (range 1‐6) in 12 of the 18 participants with initial concurrent anti‐HBs showed anti‐HBs became undetectable in 6, decreased to <10 mIU/mL in 1 and remained positive in 5 participants. Two patients lost HBsAg during follow‐up. In conclusion, prevalence of concurrent HBsAg and anti‐HBs was low at 1.2%, with anti‐HBs disappearing in some during follow‐up, in this large cohort of racially diverse children and adults with chronic HBV infection living in North America. Presence of concurrent HBsAg and anti‐HBs did not identify a specific phenotype of chronic hepatitis B, nor did it appear to affect clinical outcomes.
dc.publisherWiley Periodicals, Inc.
dc.subject.otheranti‐HBs
dc.subject.otherchronic hepatitis B
dc.titlePrevalence and clinical features of patients with concurrent HBsAg and anti‐HBs: Evaluation of the hepatitis B research network cohort
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/156489/3/jvh13312.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/156489/2/jvh13312-sup-0001-FigS1-S3.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/156489/1/jvh13312_am.pdfen_US
dc.identifier.doi10.1111/jvh.13312
dc.identifier.sourceJournal of Viral Hepatitis
dc.identifier.citedreferenceLee BS, Cho YK, Jeong S‐H, et al. Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti‐HBs. J Med Virol. 2013; 85 ( 8 ): 1327 ‐ 1333..
dc.identifier.citedreferenceHayashi J, Noguchi A, Nakashima K, et al. Frequency of concurrence of hepatitis B surface antigen and antibody in a large number of carriers in Okinawa, Japan. Gastroenterol Jpn. 1990; 25: 593 ‐ 597.
dc.identifier.citedreferenceZhang JM, Xu Y, Wang XY, et al. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype‐specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis. 2007; 44: 1161 ‐ 1169.
dc.identifier.citedreferenceColson P, Borentain P, Motte A, et al. Clinical and virological significance of the co‐existence of HBsAg and anti‐HBs antibodies in hepatitis B carriers. Virology. 2007; 367: 30 ‐ 40.
dc.identifier.citedreferenceLada O, Benhamou Y, Poynard Y, Thibault V. Coexistence of hepatitis B surface antigen (HBsAg) and anti‐HBs antibodies in chronic hepatitis B virus carriers: Influence of “a” determinant variants. J Virol. 2006; 80: 2968 ‐ 2975.
dc.identifier.citedreferenceHuang X, Qin Y, Zhang P, et al. PreS deletion mutations of hepatitis B virus in chronically infected patients with simultaneous seropositivity for hepatitis B surface antigen and anti‐HBs antibodies. J Med Virol. 2010; 82: 23 ‐ 31.
dc.identifier.citedreferenceChen Y, Qian F, Yuan Q, et al. Mutations in hepatitis B virus DNA from patients with coexisting HBsAg and anti‐HBs. J Clin Virol. 2011; 52: 198 ‐ 203.
dc.identifier.citedreferenceLiu W, Hu T, Wang X, et al. Coexistence of hepatitis B surface antigen and anti‐HBs in Chinese chronic hepatitis B virus patients relating to genotype C and mutations in the S and P gene reverse transcriptase region. Arch Virol. 2012; 157: 627 ‐ 634.
dc.identifier.citedreferenceDing F, Yu HG, Li YX, Cui N, Dai JF, Yu JP. Sequence analysis of the HBV S protein in Chinese patients with coexisting HBsAg and anti‐HBs. J Med Virol. 2015; 87: 2067 ‐ 2073.
dc.identifier.citedreferencePu Z, Li D, Wang A, et al. Epidemiological characteristics of the carriers with coexistence of HBsAg and anti‐HBs based on a community cohort study. J Viral Hepat. 2016; 23: 286 ‐ 293.
dc.identifier.citedreferenceLiu Y, Zhang L, Zhou JY, Pan J, Hu W, Zhou YH. Clinical and virological characteristics of chronic hepatitis B patients with coexistence of HBsAg and anti‐HBs. PLoS One. 2016; 11 ( 1 ): e0146980.
dc.identifier.citedreferenceFu X, Chen J, Chen H, et al. Mutation in the S gene of hepatitis B virus and anti‐HBs subtype‐nonspecificity contributed to the co‐existence of HBsAg and anti‐HBs in patients with chronic hepatitis B virus infection. J Med Virol. 2017; 89: 1419 ‐ 1426.
dc.identifier.citedreferenceLiu K, Xie M, Lu X, et al. Mutations within the major hydrophilic region (MHR) of hepatitis B virus from individuals with simultaneous HBsAg and anti‐HBs in Guangzhou, Southern China. J Med Virol. 2018; 90: 1337 ‐ 1342.
dc.identifier.citedreferenceWang YM, Ng WC, Kang JY, et al. Serological profiles of hepatitis B carrier patients in Singapore with special reference to the frequency and significance of concurrent presence of HBsAg and anti‐HBs. Singapore Med J. 1996; 37: 150 ‐ 152.
dc.identifier.citedreferenceSchwarz KB, Cloonan YK, Ling SC, et al. Children with chronic hepatitis B in the United States and Canada. J Pediatr. 2015; 167: 1287 ‐ 1294.
dc.identifier.citedreferencePancher M, Desire N, Ngo Y, et al. Coexisting of circulating HBsAg and anti‐HBs antibodies in chronic hepatitis B carriers is not a simple analytical artifact and does not influence HBsAg circulation. J Clin Virol. 2015; 62: 32 ‐ 37.
dc.identifier.citedreferenceGhany MG, Perrillo R, Li R, et al. Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. Clin Gastroenterol Hepatol. 2015; 13: 183 ‐ 192.
dc.identifier.citedreferenceGanova‐Raeva L, Ramachandran S, Honisch C, et al. Robust hepatitis B virus genotyping by mass spectrometry. J Clin Microbiol. 2010; 48: 4161 ‐ 4168.
dc.identifier.citedreferenceWasserstein RL, Schirm AL, Lazar NA. Moving to a world beyond “p<0.05”. Am Stat. 2019; 73 ( Suppl. 1 ): 1 ‐ 19.
dc.identifier.citedreferenceSeo SI, Choi HS, Choi BY, Kim HS, Kim HY, Jang MK. Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: a retrospective cohort study. J Med Virol. 2014; 86: 124 ‐ 130.
dc.identifier.citedreferenceJang JS, Kim HS, Kim HJ, et al. Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection. J Med Virol. 2009; 81: 1531 ‐ 1538.
dc.identifier.citedreferenceXiang Y, Chen P, Xia JR, Zhang LP. A large‐scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies. Genet Mol Res. 2017; 6 ( 1 ).
dc.identifier.citedreferenceGocke DJ, Hsu K, Morgan C, Bombardieri S, Lockshin M, Christian CL. Vasculitis in association with Australia antigen. J Exp Med. 1971; 134: 330 ‐ 336.
dc.identifier.citedreferenceSasaki T, Ohkubo Y, Yamashita Y, Imai M, Miyakawa Y. Co‐occurrence of hepatitis B surface antigen of a particular subtype and antibody to a heterologous subtypic specificity in the same serum. J Immunol. 1976; 117: 2258 ‐ 2259.
dc.identifier.citedreferenceLe Bouvier GL. The heterogeneity of Australia antigen. J Infect Dis. 1971; 123: 671 ‐ 675.
dc.identifier.citedreferenceKoziol DE, Alter HJ, Kirchner JP, Holland PV. The development of HBsAg‐positive hepatitis despite the previous existence of antibody to HBsAg. J Immunol. 1976; 117: 2260 ‐ 2262.
dc.identifier.citedreferenceTabor E, Gerety RJ, Smallwood LA, Barker LF. Coincident hepatitis B surface antigen and antibodies of different subtypes in human serum. J Immunol. 1977; 118: 369 ‐ 370.
dc.identifier.citedreferenceHeijtink RA, van Hattum J, Schalm SW, Masurel N. Co‐occurrence of HBsAg and anti‐HBs: two consecutive infections or a sign of advanced chronic liver disease? J Med Virol. 1982; 10: 83 ‐ 90.
dc.identifier.citedreferenceTsang TK, Blei AT, O’Reilly DJ, et al. Clinical significance of concurrent hepatitis B surface antigen and antibody positivity. Dig Dis Sci. 1986; 31: 620 ‐ 624.
dc.identifier.citedreferenceShiels MT, Taswell HF, Czaja AJ, et al. Frequency and significance of concurrent hepatitis B surface antigen and antibody in acute and chronic hepatitis B. Gastroenterol. 1987; 93: 675 ‐ 680.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jvh13312_am.pdf
Size:
359.3KB
Format:
PDF
View/Open
Name:
jvh13312-sup-0001-FigS1-S3.pdf
Size:
1.948MB
Format:
PDF
View/Open
Name:
jvh13312.pdf
Size:
366.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.